The increasing incidence of anal canal carcinomas requires better knowledge on anal human papillomavirus (HPV) infection. We aimed to assess anal canal HPV infection prevalence and risk factors among patients seen at a gastroenterology department in France.
the United States, surveillance programs indicate that during the 1992-2011 period, anal canal cancer incidence increased by 2.9% per year. 6 These observations are constant across continents in highly developed countries. 4, 7 The vast majority of anal canal cancers are squamous cell carcinomas (SCCs). 5, 6 Anal canal SCCs are recognized as human papillomavirus (HPV)-driven cancers, together with 5 other locations: cervix, penis, vagina, vulva, and oropharynx. 2 High-risk HPV (HR-HPV) oncogenic types 8 have been identified as definite human carcinogens in 80%-90% of anal canal SCCs, 2, 9 HR-HPV strain 16 (HR-HPV16) being the main causative agent. [10] [11] [12] Risk factors for anal canal SCC, mainly related to HPV carriage and its widespread sexual transmission, have been identified: high number of sexual partners, 13, 14 men with men sexual behavior, [13] [14] [15] smoking, 14 and acquired immune suppression due to human immunodeficiency virus (HIV). [16] [17] [18] However, HPV-related cancer incidence, including anal canal SCCs, is currently the highest in HIVnegative women. [5] [6] [7] 9 In a recent meta-analysis the estimated global HPV prevalence was 12% at the cervical site in women with a first peak at younger ages (<25 years) and a rebound at older ages (45 years). 19 So far, few studies have investigated HPV prevalence at the anal site in subjects without neoplastic lesion. Most of them have assessed HPV anal carriage in HIV-positive populations 17, 20 or in separate cohorts of men or women, and found that anal canal infection ranged from 12% in men to 42% in women. 13, 21, 22 Data are especially scarce in populations that are not HIV positive and not at high risk of sexually transmitted infections. Subjects seen in a Gastroenterology department offer the opportunity to study both genders at various ages and to assess other risk factors for anal HPV infection than those associated with sexual behavior, such as bowel or transit disorders, and to address HPV burden in specific diseases such as inflammatory bowel disease (IBD), Crohn's disease (CD), and ulcerative colitis (UC). In CD, the perianal area may be affected by inflammatory or penetrating lesions. Higher incidence of anal canal cancers in CD patients is strongly suggested in the literature from case series [23] [24] [25] [26] and literature reviews, 27 but evidence from population-based data is missing. HPV infection at the anal canal site, as a prelude to carcinogenesis, has not been investigated in these patients and whether patients who receive immunosuppressants carry an excess risk of viral anal infection is unknown.
The aim of our prospective study was to assess HPV prevalence and type distribution in anal canal in French men and women patients undergoing colonoscopy in a Gastroenterology department. Secondary objectives were to assess specific risk factors for anal HPV infection in this population.
Materials and Methods

Patient Recruitment and Sample Collection
Patients were prospectively recruited in the PAP-ILLAN (Human PAPILLomavirus ANal infection) study between April 1, 2012, and April 30, 2015, in a French University Hospital Gastroenterology department. Eligible patients were 18 years of age or older, and were planned to undergo colonoscopy under general anesthesia, whatever the indication of the colonoscopy was and regardless of the PAPILLAN study. This strategy of recruitment was designed to limit enrollment bias linked to discomfort related to anal canal examination and sampling. Exclusion criteria were the patient's refusal to participate in the study or his or her inability to give informed consent. This study received approval from the ethics committee (CPP-Est II) on January 19, 2012, and from the French health administration on April 13, 2012 (ClinicalTrials.gov; NCT02862795).
At the baseline visit, patients had a detailed interview regarding demographic data and medical history, coexisting diseases, immunosuppressive treatments, tobacco use, sexually transmitted infections, and gynecologic follow-up for women. On the day of the colonoscopy, all included patients were given an anonymous selfadministered questionnaire regarding their sociological background and sexual habits.
The sampling of anal canal smear was performed after anal margin examination, and before colonoscopy. A cervical sampler brush (Qiagen, Courtaboeuf, France) for HPV detection was inserted into the anal canal up to 4-5 cm from the anal margin and rotated 360 clockwise with a firm pressure while pulling it back, passing through the anorectal transition area. 28 HPV DNA Detection and Genotyping DNA was extracted using the QIAamp DNA Blood minikit (Qiagen). HPV DNA detection and genotyping were performed using the INNO-LiPA HPV Genotyping Extra kit (Fujirebio Diagnostics, Göteborg, Sweden). The HPV genotypes were classified 8 as: HR-HPV, probably HR-HPV, low-risk HPV (LR-HPV), unclassified HPV, and unrecognized genotype: HPV X (Supplemental Material).
Statistics
We analyzed data by using SAS version 9.2 (SAS Institute, Cary, NC). A sample was defined as positive if at least 1 HPV type was found. A sample was defined as HR-HPV positive if at least 1 HR-HPV type was found, excluding probably HR, unclassified, and X HPV genotypes.
Because of sparse data, factors associated with HPV DNA detection in anal canal specimens were determined for any HPV, HR-HPV, and HPV16. Fisher exact test was used to assess prevalence differences by patients' characteristics in bivariate analysis, in the total population for demographic data and medical history, and in the set of patients who answered the self-administered questionnaire for sociological and sexual data. Two outcomes were focused on in the subset of patients in which both medical history data and the self-administered questionnaire were available: HR-HPV and HPV16. The factors that were associated with outcomes at a P value level below .30 were introduced in multivariate logistic regression following a backward stepwise procedure. The level of significance was set to .05. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated for each outcome. All models were adjusted for age of the participants at entry into the study.
Results
Patient and Sample Characteristics
Five hundred and thirty-six patients were screened for the PAPILLAN study during the inclusion period. After withdrawal of patients who did not give consent to the study, those with missing data, and those who had no sample or inadequate sampling (no cellular DNA), the total population of the study was composed of 469 patients (Supplemental Figure 1) . The participants in the study consisted of 242 women (51.6%) and 227 men (48.4%), median age 54 years (interquartile range, 18-86 years). Among them, 275 completed the anonymous self-questionnaire. Indications for colonoscopy were colorectal cancer screening in asymptomatic patients for 45.6% of the population, and gastrointestinal bleeding or anemia, IBD (101 patients), and various gastrointestinal disorders for the second half (Table 1) ; 112 patients had at least 1 immunosuppressive treatment for IBD or another condition (Table 1) . At anal margin examination, no macroscopic neoplastic lesion was found. Data on coexisting diseases, gastrointestinal disorders, past proctologic conditions, sexually transmitted diseases, tobacco use, and gynecologic follow-up for women are reported in Table 1 . Only 1 patient was HIV infected. Data on sexual behavior and sociodemographic characteristics available for the 275 patients who completed the self-administered questionnaire are reported in Table 2 .
Anal Canal HPV DNA Prevalence and Genotype Distribution
Overall, 160 of 469 (34.1%) patients were positive for at least 1 HPV DNA of any type (Figure 1 (Figure 1 ). Most frequent HR-HPV types were, in decreasing order, HPV16 (n ¼ 32, 6.8%), HPV51 (n ¼ 22, 4.7%), HPV52 (n ¼ 12, 2.6%), HPV39 (n ¼ 10, 2.1%), HPV58 (n ¼ 6, 1.3%), HPV68 (n ¼ 6, 1.3%), and HPV56 (n ¼ 5, 1.1%) (Figure 2 ).
Risk Factors for Anal Canal HPV Infection: Bivariate and Multivariate Analysis
HR-HPV types were more frequently encountered in the 31-35 and 46-50 years of age groups (Supplemental Figures 2 and 3 ). In bivariate analysis age was, however, not associated with the presence of HR-HPV (P ¼ .068) ( Table 1) . Among all patients harboring HR-HPV, 65.9% were women (23.1% vs 12.8%; P ¼ .0035). HPV16 infection was also significantly more frequent in women than in men (9.5% vs 4.0%; P ¼ .017). Among patients with anal HR-HPV infection, 15% had been diagnosed with another sexually transmitted infection in their lifetime (P ¼ .0036), 25% if HPV16 anal infection alone was considered (P ¼ .0002) ( Table 1 
Anal Canal HPV Infection in the IBD Population
In our study population, 101 patients (43 men, 58 women) had IBD; 70 patients had CD, including 22 (31.4%) with an active or former perianal involvement, 29 patients had UC, and 2 had an undetermined colitis (Table 4) . HPV DNA of any type was identified in 35 of 101 (34.7%) IBD patients' samples, of which 24 (68.6%) were women. The prevalence of anal canal HR-HPV and HPV16 infection in UC patients did not differ from that in non-IBD patients (13.8% vs 18.1%, P ¼ .755; and 3.0% vs 6.8%, P ¼ .712, respectively). In bivariate analysis, CD patients had anal canal HR-HPV and HPV16 infection significantly more often than the rest of the population did (30.0% vs 18.1%, P ¼ .005; and 14.0% vs 6.8%, P ¼ .007, respectively) ( Table 4 ). In our cohort, 22 patients had CD with perianal involvement, and among them 11 had HPV DNA in the anal canal (50%) vs 24 of 79 (30.4%) for other IBD patients (P ¼ .12). Seven of them were infected with HR-HPV (31.8%, 6 were women) vs 24% for other IBD patients (P ¼ .58). Active smoking was not significantly more frequent in the CD population compared with the rest of our PAPILLAN study population (30% vs 20.2%; p ¼ .083). In bivariate analysis in CD, active smoking was significantly associated with HR-HPV infection and female sex with HPV16 infection (Table 4) .
Overall, 84 of 101 (83.2%) IBD patients received immunosuppressive therapy at the time of the study (75.8% vs 85.7% for UC and CD patients, respectively; P ¼ .25); 64.4% of the patients had been exposed (past or present) to thiopurines (51.7% in UC and 68.6% in CD; P ¼ .16). Among exposed patients, 30.8% had an infection with HR-HPV vs 16.6% of nonexposed patients (P ¼ .15) ( Table 4) . 
Discussion
In the PAPILLAN study population of female and male patients undergoing colonoscopy (median 54 years of age), HPV DNA of any type was detected in the anal canal of one-third of the patients, with a significantly higher prevalence in women. Oncogenic HR-HPV subtypes, known to lead to intraepithelial neoplasia and anal cancer, were detected in 1 of 5 patients. HPV16 was by far the most prevalent genotype, affecting 1 in 10 women.
Infections with mucosal HPVs are the most common sexually transmitted infections worldwide.
2 Genital infections with oncogenic HPV types in women are responsible for cervix, vulva, and vagina carcinomas through a low grade-high grade intraepithelial neoplasia pattern leading to invasive cancer and dependent on HPV integration in host cells. 29 High prevalence of HPV infection in anal canal corroborates its involvement in anal carcinogenesis, previously suggested by epidemiological association studies in large series of anal canal SCCs worldwide. 10, 11 In this cohort, we used a HPV detection and genotyping method with high analytic sensitivity and specificity, 30 suitable for this type of epidemiological study. 10, 11 Previously the prevalence of anal canal HPV infection had been assessed specifically in non-HIV women in the Hawai'i population attending a gynecology clinic. 31 It had also been assessed in non-HIV men who had sex with women in the "HPV in men" cohort. 13 Comparisons between studied populations should be done with caution. Various HPV molecular detection methods with various levels of sensitivity are used and may account for discrepancies. Also, anal smear sampling may not reach the anal canal transitional area, reservoir of the virus, if the brush is not properly inserted through the anal canal toward the rectum. 28 Finally, populations may vary in sociodemographic and sexual habits, depending on the mode of recruitment of the study participants. Interestingly, our study conducted in a female and male population allowed us, for the first time, to compare both genders and to support the over-representation of women in anal canal SCCs epidemiology. We unequivocally confirmed that female gender was associated with anal canal HPV infection by those genotypes which are responsible for anal canal SCCs. 10 As previously reported in a HIV seronegative cohort of men who have sex with men, 14 we found that active smoking was an independent risk factor for anal HPV infection. Tobacco was also reported as a risk factor in anal canal cancers. 32 As HR-HPVs are sexually transmitted, it might be expected that their presence in anal canal could be correlated to previous history of other sexually transmitted infections and the number of past year and lifetime sex partners. 13, 21, 22, 31 We actually confirmed this correlation in a population that was not recruited in a specialized unit for gynecological disorders or sexually transmitted diseases, reinforcing the significance of the association. In our study, sexual behavior was self-reported by only 59% of patients and to avoid possible biases, the multivariate analysis was restricted to this subset of patients. This certainly represents a limitation of the study. Also, the practical impact of HPV infection depends on the clearance rate of HPV and subsequent pathological changes in the anal canal mucosa. Both are currently being studied longitudinally in our cohort of patients.
In our population of tertiary center patients undergoing colonoscopy, 101 patients had IBD, including 70 CD patients. Many case series [23] [24] [25] [26] suggest an increased incidence of anal carcinomas in CD, but solid population-based evidence is lacking. Eleven studies from referral centers were recently reviewed 27 : the incidence of SCC was estimated at 0.02 per 1000 patient-years in CD compared with 0.009 per 1000 patient-years in UC; 85% of CD cases presented with perianal disease, the male-female ratio was 3:17. Still, prevalence of anal HPV in the IBD population had never been reliably established. In our study, CD patients, but not UC patients, had significantly more HR-HPV DNA detected in the anal canal than did the rest of the population, with 70% of HPV16 carriers being women. CD-related anal cancers may be driven by HPV infection, 33 associated with other specific disease-related mechanisms that include local and systemic chronic inflammation, 34 tobacco use, and a possible contribution of drug-induced immunosuppression. 35 The role of immunosuppression on HPV-related diseases has already been addressed in HIV patients 36, 37 or renal transplant recipients. 38 Recently, Shah et al 39 failed to demonstrate the influence of immunosuppressive therapy on the presence of anal cytological lesions in IBD patients but only few abnormal anal smears were reported in this cohort, all of them showing atypical squamous cells of undetermined significance, which limits the conclusions. Conversely, in our large cohort recruited in a Gastroenterology unit, immunosuppressive therapy was an independent risk factor for HR-HPV infection in the anal canal site. Various innate and adaptive immune host defenses are involved in controlling early HPV infections. 40 While most individuals acquire HPV infection, only about 10%-15% of them will establish persistent infection that may progress to invasive cancer. This suggests that host immune defense mechanisms are essential to clear initial HPV infection and their impairment is a potential factor to HPV persistence and carcinogenesis. 40 Although HPV infection was twice more frequent in patients ever exposed to thiopurines, immunosuppressive therapy was not significantly associated with HPV carriage in our IBD patients specifically. However, most of these patients (83%) were on immunosuppressive therapy, which markedly affected statistical power. Another limitation of our study is the relative small number of CD patients with a perianal involvement preventing us from drawing conclusion on HPV infection in this subgroup of interest with high prevalence of anal HR-HPV infection. Further large-scale research in higher numbers of IBD patients, from different regions of the world, under different treatment regimens, may allow us to specify Anal canal HPV infection, including HR types is frequent. HR-HPV infection is significantly more prevalent in CD patients. Female sex, sexual behavior, tobacco, and immunosuppressive treatments are independent risk factors for anal HPV infection. Increased prevalence of HR-HPV infection in some groups of interest could result in higher incidence of anal cancer. This should be proved by further independent studies. In the context of the rising incidence of anal canal SCCs in many parts of the world, our data strongly support the potential benefit of a broader HPV vaccination policy.
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